Jacobson Pharma Corporation Limited (2633.HK) Comparison with companies in other sectors?

Jacobson Pharma Corporation Limited has a share price of 1.99B. You can analyze Jacobson Pharma Corporation Limited (2633.HK) competitors across different market sectors through stock heatmaps.

What are 2633.HK's NET and operating margins?

Jacobson Pharma Corporation Limited (2633.HK) operating margin is around 0.24, and net profit margin is approximately 0.19 as of the latest reports.

In what way does 2633.HK's earnings per share (EPS) trend reflect its financial momentum?

Jacobson Pharma Corporation Limited (2633.HK) EPS is 0.15 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Jacobson Pharma Corporation Limited is 10.93, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Jacobson Pharma Corporation Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Jacobson Pharma Corporation Limited like P/E which is 10.82, P/B which is 1.33, and PEG which is 0.70. Compare them with sector averages to evaluate if the stock is priced fairly.

Jacobson Pharma Corporation Limited

2633.HK•HKSE

Healthcare

Drug Manufacturers - Specialty & Generic

HK$1.67

HK$0.00(0.00%)

Jacobson Pharma Corporation Limited (2633.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.15

P/E Ratio

10.93

ROE

0.12%

Net Margin

0.19%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$3.27B

Shares OutstandingTotal number of shares issued

$1.99B

Book Value/ShareNet worth per share

$1.25

Revenue/ShareAnnual revenue per share

$0.79

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.15

Net MarginNet income as percentage of revenue

19.08%

Operating MarginOperating income as percentage of revenue

23.99%

ROEReturn on shareholders' equity

12.32%

ROAReturn on total assets

8.25%

ROCEReturn on capital employed

12.23%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.22

Cash/ShareCash and equivalents per share

$0.26

FCF YieldFree cash flow as percentage of market cap

13.15%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.07

Dividend YieldAnnual dividend as percentage of stock price

3.96%

Financial Ratios Analysis data is not available for 2633.HKFinancial Ratios Analysis details for 2633.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2633.HKSector Benchmarking details for 2633.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Jacobson Pharma Corporation Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Jacobson Pharma Corporation Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Jacobson Pharma Corporation Limited's unique business strengths and challenges.

Key Financial Metrics for Jacobson Pharma Corporation Limited

For Jacobson Pharma Corporation Limited, essential financial indicators include EPS 0.15, PE 10.93, and ROE 0.12. These key ratios reveal insights into Jacobson Pharma Corporation Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Jacobson Pharma Corporation Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Jacobson Pharma Corporation Limited

Metrics like Net Margin 19.08% and ROA 8.25% shed light on how well Jacobson Pharma Corporation Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Jacobson Pharma Corporation Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Jacobson Pharma Corporation Limited

Using ratios such as P/B Ratio 1.33 and PEG Ratio 0.70, investors can assess whether Jacobson Pharma Corporation Limited is appropriately valued based on its financials and growth potential. These figures, combined with Jacobson Pharma Corporation Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Jacobson Pharma Corporation Limited

Financial health indicators, such as Debt/Equity Ratio 0.32 and Cash Flow $0.22, provide a snapshot of Jacobson Pharma Corporation Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Jacobson Pharma Corporation Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Jacobson Pharma Corporation Limited

Investing in Jacobson Pharma Corporation Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Jacobson Pharma Corporation Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;